Arthur T. Sands, M.D., Ph.D. is the former CEO of Lexicon Pharmaceuticals, a company he co-founded in 1995. With an M.D. and Ph.D. from Baylor College of Medicine, he has a solid background in medicine and research. Under his leadership,...

Arthur T. Sands, M.D., Ph.D. is the former CEO of Lexicon Pharmaceuticals, a company he co-founded in 1995. With an M.D. and Ph.D. from Baylor College of Medicine, he has a solid background in medicine and research. Under his leadership, Lexicon focused on developing new drugs, especially for various diseases. He initiated plans for succession as CEO in 2014, which shows his commitment to the company’s future. Sands was known for holding a significant amount of stock, with his holdings peaking at about $1.77 million in January 2021. However, his compensation fluctuated over the years, with totals reaching over $1.8 million at times, but he often did not receive bonuses when performance metrics weren't met, which reflects a performance-based approach. While leading Lexicon, Sands experienced both peaks and valleys in his financial holdings and compensation, indicating the challenging nature of the biotech industry. His tenure is marked by both innovation in drug discovery and the complexities of running a biopharma company.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Lexicon Pharmaceuticals CEOs

L

Arthur T. Sands, M.D., Ph.D.

Founder and Ex-CEO of Lexicon Pharmaceuticals

Education

M.D. and Ph.D. from Baylor College of Medicine.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

December 15, 1960 - 64 years ago

CEO of Lexicon Pharmaceuticals for

19 years 0 months (Jul 1995 - Jul 2014)

Previous Experience

Co-founder and CEO of Lexicon Pharmaceuticals since its inception.

Rivals

Competitors/colleagues of Arthur T. Sands, M.D., Ph.D.

Holdings

See how much did Arthur T. Sands, M.D., Ph.D. make over time.

Arthur T. Sands, as CEO, held significant stock positions, peaking at about $1.77 million in January 2021. His insider trading also showed varied activity, with large trades around $2.31 million in February 2021. Over time, he witnessed fluctuations in holdings,...

Arthur T. Sands, as CEO, held significant stock positions, peaking at about $1.77 million in January 2021. His insider trading also showed varied activity, with large trades around $2.31 million in February 2021. Over time, he witnessed fluctuations in holdings, notably a decrease to around $383,000 by September 2024. His stock ownership, combined with compensation that depended heavily on performance, reflects the financial risks typical in pharma. Notably, Sands’ stock values were primarily linked to Lexicon's drug development successes, creating a direct connection between his wealth and the company's performance.

Insider Trading

See recent insider trades of Arthur T. Sands, M.D., Ph.D..

LXRX

38,674 shares

LXRX

Feb 23, 2011

Received

Compensation History

See how much did Arthur T. Sands, M.D., Ph.D. make over time.

Arthur T. Sands’ compensation at Lexicon Pharmaceuticals varied widely over the years. In 2014, he earned about $1.02 million, but no bonuses were awarded due to unmet performance targets. His salary alone was $301,154 that year, highlighting that his pay was closely tied to the company's performance. In contrast, in 2013, his total compensation was much higher at $1.77 million, bolstered by stock options and vested awards, giving him a chance to benefit from the company's successes. From 2010 to 2014, his compensation often included substantial equity rewards, showcasing the typical ‘at-risk’ structure in executive pay in the biotech sector. Interestingly, when times were tough for the company, such as in 2008, his bonuses were zero, indicating a shared risk model.

Year

2014

Total Compensation

$1.02M

Salary

$301.15K

Board Justification

The compensation philosophy aims to attract and retain key executives while aligning their interests with those of shareholders through performance-based incentives.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2014 due to performance metrics not being met.

Other

$717.32K

Board Justification

This includes severance payments, compensation for unused paid time off, COBRA benefits, and consulting fees.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards were granted or vested in 2014.

Performance Metrics

Performance metrics for 2014 were not met, resulting in no bonuses or stock awards for the CEO.

Other Lexicon Pharmaceuticals CEOs

Here are other CEOs of Lexicon Pharmaceuticals

Lonnel Coats

Ex-CEO of Lexicon Pharmaceuticals

July 2014 - July 2024